CPHI 2026 – 23/07/2026
PCI Drug-Device 28/05/2026

Current Edition

ramusmedical
Europe

Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations

Invivoscribe Technologies, Inc. announced today that they have submitted to Japan's Pharmaceutical and Medical Devices Agency (PMDA) and the US Food and Drug Administ...
Continue Reading →
news

OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy

OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug ...
Continue Reading →
news

CRISPR Therapeutics Announces Planned European Clinical Trial

CRISPR Therapeutics today announced the submission of a Clinical Trial Application (CTA) today for CTX001 in β-thalassemia. CTX001 is an investigational CRISPR gene-e...
Continue Reading →
Quotient
CPHI 2026 – 20/07/2026